Фармакотерапия стабильной хронической обструктивной болезни легких: клинические рекомендации Испанского общества пульмонологов и торакальных хирургов

Полный текст:


Аннотация

По материалам: M.Miravitlles, J.J.Soler>Catalun~a, M.Calle et al. Spanish COPD Guidelines (GesEPOC): Pharmacological treatment of stable COPD. Arch. Bronconeumol. 2012; 48 (7): 247–257.


Об авторе

статья Редакционная

Россия


Список литературы

1. Chapman K.R., Mannino D.M., Soriano J.B. et al. Epi demiology and costs of chronic obstructive pulmonary dis ease. Eur. Respir. J. 2006; 27: 188–207.

2. Miravitlles M., Calle M., Soler/Cataluña J.J. Clinical phe notypes of COPD. Identification, definition and implica tions for guidelines. Arch. Bronconeumol. 2012; 48: 86–98.

3. Estrategia en, EPOC., del Sistema Nacional de Salud. Plan de Calidad para el Sistema Nacional de Salud. Ministerio de Sanidad y Politica Social; 2009.

4. Grupo de trabajo GESEPOC. Haciaunnuevo enfoque en el tratamiento de la EPOC. La Guia Española de la EPOC (GESEPOC). Arch. Bronconeumol. 2011; 47: 379–381.

5. Peces/Barba G., Barberа J.A., Agusti A. et al. Guia Clinica SEPARALAT de diagnуstico y tratamiento de la EPOC. Arch. Bronconeumol. 2008; 44: 271–281.

6. Grupo de trabajo de la guia de practica clinica sobre Atenciуn Integral al paciente con Enfermedad Pulmonar Obstructiva Crуnica (EPOC). Sociedad Española de Neumologia y Cir ugia Toracica (SEPAR) y Sociedad Española de Medicina de Familia (semFYC). 2010.

7. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstruc tive Lung Disease (GOLD); 2011 [accessed 13 March 2012]. Available from: http://www.goldcopd.org

8. Han M.K., Agusti A., Calverley P.M. et al. Chronic obstruc tive pulmonary disease phenotypes. The future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182: 598–604.

9. Pistolesi M., Bigazzi F., Cestelli L. et al. Phenotypes of chronic obstructive pulmonary disease. Hot Top Respir. Med. 2010; 5: 7–11.

10. Lopez/Campos J.L. Estrategias de tratamiento en la enfer medad pulmonar obstructiva crуnica: una propuesta de sis tematizaciуn. Arch. Bronconeumol. 2010; 46: 617–620.

11. Anderson D., MacNee W. Targeted treatment in COPD: amultisystem approach for a multisystem disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2009; 4: 321–335.

12. Miravitlles M. Tratamiento individualizado de la EPOC: una propuesta de cambio. Arch. Bronconeumol. 2009; 45 (5, Suppl.): 27–34.

13. Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exac erbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128–1138.

14. Soler Cataluña J.J., Martinez Garcia M.A., Catalan Serra P. The frequent exacerbator. A new phenotype in COPD? Hot Top Respir. Med. 2011; 6: 7–12.

15. Quint J.K., Donaldson G.C., Hurst J.R. et al. Predictive accuracy of patientreported exacerbation frequency in COPD. Eur. Respir. J. 2011; 37: 501–507.

16. Gibson P.G., Simpson J.L. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64: 728–735.

17. Miravitlles M. The overlap syndrome between asthma and COPD: implications for management. Hot Top Respir. Med. 2011; 6: 15–20.

18. O'Donnell D.E., Aaron S., Bourbeau J. et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. Can. Respir. J. 2007; 14 (Suppl. B): 5B–32B.

19. Guidelines for the diagnosis and treatment of COPD / Nagai A., Aizawa H., Aoshiba K. et al. 3rd ed. Tokyo: The Japanese Respiratory Society, Medical Review Co. Ltd.; 2009.

20. Soler/Cataluña J.J., Cosio B., Izquierdo J.L. et al. Documento de consenso sobre el fenotipo mixto EPOCasma en la EPOC. Arch. Bronconeumol. 2012, http://dx.doi.org/10.1016/j.arbres.2011.12.009

21. Han M.K., Kazerooni E.A., Lynch D.A. et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology 2011; 261: 274–282.

22. Nishimura M., Makita H., Nagai K. et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012; 185: 44–52.

23. American Thoracic Society. Chronic bronchitis, asthma, and pulmonary emphysema, a statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases. Am. Rev. Respir. Dis. 1962; 85: 762–768.

24. Prescott E., Lange P., Vestbo J. Chronic mucus hypersecre tion in COPD and death from pulmonary infection. Eur. Respir. J. 1995; 8: 1333–1338.

25. Miravitlles M. Cough and sputum production as risk factors for poor outcomes in patients with COPD. Respir. Med. 2011; 105: 1118–1128.

26. Montes de Oca M., Halbert R.J., Lуpez M.V. et al. Chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur. Respir. J. 2012. http://dx.doi.org/10.1183/09031936.00141611

27. Kim V., Han M.K., Vance G.B. et al. The chronic bronchitic phenotype of COPD. An analysis of the COPDGene study. Chest 2011; 140: 626–633.

28. Patel I.S., Vlahos I., Wilkinson T.M.A. et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstruct tive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 70: 400–407.

29. Martinez/Garcia M.A., Soler/Cataluña J.J., Donat Y. et al. Factors associated with bronchiectasis in chronic obstructive pulmonary disease patients. Chest 2011; 140: 1130–1137.

30. Celli B.R., Cote C.G., Marin J.M. et al. The bodymass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 1005–1012.

31. Soler/Cataluña J.J., Martinez/Garcнa M.A., Sánchez L. et al. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir. Med. 2009; 103: 692–699.

32. Bestall J.C., Paul E.A., Garrod R. et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as amea sure of disability in patients with chronic obstructive pul monary disease. Thorax 1999; 54: 581–586.

33. Nishimura K., Izumi T., Tsukino M., Oga T. Dyspnea is a better predictor of 5year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434–1440.

34. Esteban C., Quintana J.M., Aburto M. et al. Impact of changes in physical activity on healthrelated quality of life among patients with COPD. Eur. Respir. J. 2010; 36: 292–300.

35. Garcia/Aymerich J., Lange P., Benet M. et al. Regular phys ical activity modifies smokingrelated lung function decline and reduces risk of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 175: 458–463.

36. Watz H., Waschki B., Meyer T., Magnussen H. Physical activ ity in patients with COPD. Eur. Respir. J. 2009; 33: 262–272.

37. Garcнa/Aymerich J., Serra Pons I., Mannino D.M. et al. Lung function impairment. COPD hospitalisations and subsequent mortality. Thorax 2011; 66: 585–590.

38. Jones P.W., Harding G., Berry P. et al. Development and first validation of the COPD Assessment Test. Eur. Respir. J. 2009; 34: 648–654.

39. Jones P.W., Brusselle G., Dal Negro R.W. et al. Properties of the COPD Assessment Test in a crosssectional European study. Eur. Respir. J. 2011; 38: 29–35.

40. Postma D., Anzueto A., Calverley P. et al. A new perspective on optimal care for patients with COPD. Prim. Care Respir. J. 2011; 20: 205–209.

41. Appleton S., Jones T., Poole P. et al. Ipratropium bromide versus short acting beta2agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; 2:CD001387.

42. Stockley R.A., Whitehead P.J., Williams M.K. Improved out comes in patients with chronic obstructive pulmonary dis ease treated with salmeterol compared with placebo / usual therapy: results of a metaanalysis. Respir. Res. 2006; 7: 147.

43. Aalbers R., Ayres J., Backer V. et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3month trial. Eur. Respir. J. 2002; 19: 936–943.

44. Tashkin D.P., Celli B., Senn S. et al. A 4year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543–1554.

45. Beier J., Beeh K.M. Longacting βadrenoceptor agonists in the management of COPD: focus on indacaterol. Int. J. Chron. Obstruct. Pulm. Dis. 2011; 6: 237–243.

46. Brusasco V., Hodder R., Miravitlles M. et al. Health out comes following six months treatment with once daily tiotropium compared to twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399–404.

47. Puhan M.A., Bachmann L.M., Kleijnen J. et al. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network metaanalysis. BMC Med. 2009; 7: 2.

48. Wilt T.J., Niewoehner D., MacDonald R., Kane R.L. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann. Intern. Med. 2007; 147: 639–653.

49. Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364: 1093–1103.

50. Van Noord J.A., Aumann J./L., Janssens E. et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J. 2005; 26: 214–222.

51. Van Noord J.A., Buhl R., LaForce C. et al. QVA149 demon strates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010; 65: 1086–1091.

52. Zhou Y., Wang X., Zeng X. et al. Positive benefits of theo phylline in a randomized, doubleblind, parallelgroup, placebocontrolled study of lowdose, slowrelease theo phylline in the treatment ofCOPDfor 1 year. Respirology 2006; 11: 603–610.

53. Ram F.S.F., Jardim J.R., Atallah A. et al. Efficacy of theo phylline in people with stable chronic obstructive pul monary disease: a systematic review and metaanalysis. Respir. Med. 2005; 99: 135–144.

54. American Thoracic Society. European Respiratory Society Statement: standards for the diagnosis and management of individuals with alpha1antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 2003; 168: 818–900.

55. Vidal R., Blanco I., Casas F. et al. Guidelines for the diag nosis and management of alpha1antitrypsin deficiency. Arch. Bronconeumol. 2006; 42: 645–659.

56. Hardin M., Silverman E.K., Barr R.G. et al. The clinical fea tures of overlap between COPD and asthma. Respir. Res. 2011; 12: 127.

57. Papi A., Romagnoli M., Baraldo S. et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 162: 1773–1777.

58. Siva R., Green R.H., Brightling C.E. et al. Eosinophilic air way inflammation and exacerbations of COPD: a random ized controlled trial. Eur. Respir. J. 2007; 29: 906–913.

59. Miravitlles M. Arguments in favor of inhaled corticosteroids in COPD by phenotype instead of by severity. Arch. Bronconeumol. 2011; 47: 271–273.

60. Welte T., Miravitlles M., Hernandez P. et al. Efficacy and tol erability of budesonide / formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180: 741–750.

61. Peters S.P., Kunselman S.J., Nikolina Icitovic M.A. et al. Tiotropium bromide stepup therapy for adults with uncon trolled asthma. N. Engl. J. Med. 2010; 363: 1715–1726.

62. Calverley P.M.A., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775–778.

63. Kardos P., Wencker M., Glaab T., Vogelmeier C. Impact of salmeterol / fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary dis ease. Am. J. Respir. Crit. Care Med. 2007; 175: 144–149.

64. Nannini L.J., Cates C.J., Lasserson T.J., Poole P. Combined corticosteroid and longacting betaagonist in one inhaler versus longacting betaagonists for chronic obstructive pul monary disease. Cochrane Database Syst. Rev. 2007; 4: CD006829.

65. Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tio tropium in combination with placebo, salmeterol, or fluti casonesalmeterol for treatment of chronic obstructive pul monary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545–555.

66. Calverley P.M.A., Sanchez/Toril F., McIvor A. et al. Effect of 1year treatment with roflumilast in severe chronic obstruct tive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 176: 154–161.

67. Rennard S.I., Calverley P.M.A., Goehring U.M. et al. Reduction of exacerbations by the PDE4 inhibitor roflumi last – the importance of defining different subsets of patients with COPD. Respir. Res. 2011; 12: 18.

68. Fabbri L.M., Calverley P.M.A., Izquierdo/Alonso J.L. et al. Roflumilast in moderatetosevere chronic obstructive pul monary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695–703.

69. Bateman E.D., Rabe K.F., Calverley P.M. et al. Roflumilast with longacting b2agonists for COPD: influence of exac erbation history. Eur. Respir. J. 2011; 38: 553–560.

70. Grandjean E.M., Berthet P., Ruffmann R., Leuenberger P. Efficacy of oral longterm Nacetylcysteine in chronic bronchopulmonary disease: a metaanalysis of published doubleblind, placebocontrolled clinical trials. Clin. Ther. 2000; 22: 209–221.

71. Poole P.J., Black P.N. Mucolytic agents for chronic bron chitis or chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; 3: CD001287.

72. Zheng J.P., Kang J., Huang S.G. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomized placebocontrolled study. Lancet 2008; 371: 2013–2018.

73. Decramer M., Rutten/van M.M., Dekhuijzen P.N. et al. Effects of Nacetylcysteine on outcomes in chronic obstruc tive pulmonary disease (Bronchitis Randomized on NAC CostUtility Study. BRONCUS): a randomized placebo controlled trial. Lancet 2005; 365: 1552–1560.

74. Staykova T., Black P.N., Chacko E.E., Poole P. Prophylactic antibiotic therapy for chronic bronchitis. Coch. Rev. Published online: 21 Jan. 2009. http://dx.doi.org/10.1002/14651858.CD004105

75. Sevilla/Sanchez D., Soy/Muner D., Soler/Porcar N. Utilidad de los macrуlidos como antiinflamatorios en las enfer medades respiratorias. Arch. Bronconeumol. 2010; 46: 244–254.

76. Pomares X., Montуn C., Espasa M. et al. Longtermazithro mycin therapy in patients with severe COPD and repeated exacerbations. Int. J. Chron. Obstruct. Respir. Dis. 2011; 6: 449–456.

77. Seemungal T.A.R., Wilkinson T.M.A., Hurst J.R. et al. Long term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exa cerbations. Am. J. Respir. Crit. Care Med. 2008; 178: 1139–1147.

78. Albert R.K., Connett J., Biley W.C. et al. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 365: 689–698.

79. Miravitlles M., Marin A., Monsу E. et al. Efficacy of moxi floxacin in the treatment of bronchial colonization in COPD. Eur. Respir. J. 2009; 34: 1066–1071.

80. Sethi S., Jones P.W., Theron M.S. et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir. Res. 2010; 11: 10.

81. Vendrell M., de Gracia J., Olveira C. et al. Diagnуstico y tratamiento de las bronquiectasias. Arch. Bronconeumol. 2008; 44: 629–640.

82. Adams S.G., Anzueto A., Briggs Jr. D.D. et al. Evaluation of withdrawal of maintenance tiotropium in COPD. Respir. Med. 2009; 103: 1415–1420.

83. Van der Valk P., Monninkhof E., van del Palen J. et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. The COPE study. Am. J. Respir. Crit. Care Med. 2002; 166: 1358–1363.

84. Nighat J., Nadeem N.J., Taylor S., Eldridge S.M. Withdrawal of inhaled corticosteroids in individuals with COPD – a sys tematic review and comment on trial methodology. Respir. Res. 2011; 12: 107.

85. Schermer T.R.J., Hendriks A.J.C., Chavannes N.H. et al. Probability and determinants of relapse after discontinua tion of inhaled corticosteroids in patients with COPD treat ed in general practice. Prim. Care Respir. J. 2004; 13: 48–55.

86. Liesker J.J.W., Bathoorn E., Postma D.S. et al. Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD. Respir. Med. 2011; 105: 1853–1860.


Дополнительные файлы

Для цитирования: Редакционная с. Фармакотерапия стабильной хронической обструктивной болезни легких: клинические рекомендации Испанского общества пульмонологов и торакальных хирургов.  Пульмонология. 2012;(5):11-22.

For citation: . Pharmacotherapy of stable chronic obstructive pulmonary disease: clinical guidelines of Spanish Society of Pulmonology and Thoracic Surgery. Russian Pulmonology. 2012;(5):11-22. (In Russ.)

Просмотров: 334

Обратные ссылки

  • Обратные ссылки не определены.


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)